View Financial HealthThis company listing is no longer activeThis company may still be operating, however this listing is no longer active. Find out why through their latest events.See Latest EventsEpiphany Technology Acquisition 배당 및 자사주 매입배당 기준 점검 0/6핵심 정보n/a배당 수익률-1.2%자사주 매입 수익률총 주주 수익률-1.2%미래 배당 수익률n/a배당 성장률n/a다음 배당 지급일n/a배당락일n/a주당 배당금n/a배당 성향n/a최근 배당 및 자사주 매입 업데이트업데이트 없음모든 업데이트 보기Recent updates공시 • Jan 14Epiphany Technology Acquisition Corp.(NasdaqCM:EPHY) dropped from NASDAQ Composite IndexEpiphany Technology Acquisition Corp. has been dropped from NASDAQ Composite Index .Board Change • Dec 31High number of new and inexperienced directorsThere are 10 new directors who have joined the board in the last 3 years. The company's board is composed of: 10 new directors. 2 experienced directors. No highly experienced directors. Co-CEO, CFO & Director Peter Bell is the most experienced director on the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.공시 • Sep 24Epiphany Technology Acquisition Corp. Appoints Board of DirectorsEffective September 16, 2022, the board of directors of Epiphany Technology Acquisition Corp. approved an increase in the size of the Board from seven (7) directors to eleven (11) directors and elected Ross Haghighat, Stephen Sherwin, Louis Lange and Ronald Eastman as members of the Board to fill the vacancies created by the increase. The Board determined that each Messrs. Stephen Sherwin, Louis Lange and Ronald Eastman is an “independent director” as defined in the Nasdaq listing standards and applicable rules of the Securities and Exchange Commission. Ross Haghighat has served as Chief Executive Officer, Chief Financial Officer and a Director of BioPlus Acquisition Corp. since December 2021. Mr. Haghighat is the founding partner at Jasper Capital Partners and Chairman of Triton Systems Inc. Mr. Haghighat has been a founder, co-founder, and board member of more than a dozen private and public technology companies in the US, Europe, China and Australia. During Mr. Haghighat’s expansive career as an operator, he generated billions in shareholder value through his roles transforming companies from early-stage technology firms to successful corporations, as well as integrated divisions of Fortune 500 companies. From 1994 to 2001, Mr. Haghighat co-founded and led CoreTek Inc. Mr. Haghighat currently serves on the Board of Directors at Chinook Therapeutics Inc., where Mr. Haghighat is Chairman of the Transaction Committee; CITIC Capital Acquisition Corp., where Mr. Haghighat also serves as Chair of the Audit Committee of Fluence Corporation Ltd., where Mr. Haghighat serves as Vice Chairman; Angel Medical Systems Inc., where Mr. Haghighat serves as Lead Director and FRX Polymers Inc., where Mr. Haghighat serves as Chairman. Mr. Haghighat received a Bachelor of Science in Advanced Materials Engineering from Rutgers University and Master of Science in Organometalic Chemistry from Rutgers University, as well as an MBA from Boston College — Wallace E Carroll School of Management. Mr. Haghighat is well qualified to serve on the Board due to his extensive operating, investing and board experience in the biotechnology industry. Ronald Eastman Since December 2021, Ronald Eastman has served as Vice Chairman of BioPlus Acquisition Corp. Mr. Eastman has over 40 years of experience in building and leading both publicly-traded and private healthcare businesses. Mr. Eastman is currently a Senior Advisor of EW Healthcare Partners (EW), where he previously served for 15 years as Managing Director of multiple funds before transitioning to Senior Advisor in 2021. Mr. Eastman led and served on the Board of Directors of EW’s investments in ProteinSimple Inc. (acquired by Bio-Techne Corporation), Corium Inc. (acquired by Gurnet Point Capital), and Open Monoclonal Technology Inc. (acquired by Ligand Pharmaceuticals Inc.). He also currently serves on the Board of Directors of EW portfolio company Suneva Medical Inc. Mr. Eastman began his career at American Cyanamid Company, which was acquired by American Home Products (now Pfizer Inc.), where Mr. Eastman spent 15 years managing various pharmaceutical products, divisions, and subsidiaries in the U.S. and overseas. Later as CEO of Geron Corporation, Mr. Eastman led the company’s growth from a venture-backed start-up to a publicly traded pioneer in the fields of regenerative medicine and cancer. As CEO of Rinat Neuroscience Corporation with the support of EW in late 2001, Mr. Eastman led the effort to build the first company dedicated to discovering and developing large molecule drugs for treating nervous system disorders. Rinat Neuroscience was acquired by Pfizer Inc. in 2006. Mr. Eastman has also previously served as a board member of Revance Therapeutics Inc., the Biotechnology Innovation Organization, and as a Trustee of the Buck Institute for Research on Aging. Mr. Eastman has a Bachelor of Arts degree from Williams College and a Master of Business Administration degree from Columbia University. Mr. Eastman is well qualified to serve on the Board due to his extensive operating, investing and board experience in the biotechnology industry.공시 • Sep 23Epiphany Technology Acquisition Corp. Appoints Ross Haghighat as Co-Chief Executive OfficerThe board appointed Mr. Ross Haghighat as Co-Chief Executive Officer of Epiphany Technology Acquisition Corp., effective September 16, 2022. Ross Haghighat has served as Chief Executive Officer, Chief Financial Officer and a Director of BioPlus Acquisition Corp. since December 2021. Mr. Haghighat is the founding partner at Jasper Capital Partners and Chairman of Triton Systems Inc. Mr. Haghighat has been a founder, co-founder, and board member of more than a dozen private and public technology companies in the US, Europe, China and Australia. During Mr. Haghighat’s expansive career as an operator, he generated billions in shareholder value through his roles transforming companies from early-stage technology firms to successful corporations, as well as integrated divisions of Fortune 500 companies. From 1994 to 2001, Mr. Haghighat co-founded and led CoreTek Inc. Mr. Haghighat currently serves on the Board of Directors at Chinook Therapeutics Inc., where Mr. Haghighat is Chairman of the Transaction Committee; CITIC Capital Acquisition Corp., where Mr. Haghighat also serves as Chair of the Audit Committee of Fluence Corporation Ltd., where Mr. Haghighat serves as Vice Chairman; Angel Medical Systems Inc., where Mr. Haghighat serves as Lead Director and FRX Polymers Inc., where Mr. Haghighat serves as Chairman. Mr. Haghighat received a Bachelor of Science in Advanced Materials Engineering from Rutgers University and Master of Science in Organometalic Chemistry from Rutgers University, as well as an MBA from Boston College — Wallace E Carroll School of Management. Mr. Haghighat is well qualified to serve on the Board due to his extensive operating, investing and board experience in the biotechnology industry.공시 • Jun 05Epiphany Technology Acquisition Announces Receipt of Notice from Nasdaq Regarding Late Filing of Quarterly Report on Form 10-QEpiphany Technology Acquisition Corp. announced that it has received a notice (“Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market (“Nasdaq”) as a result of its failure to file its Quarterly Report on Form 10-Q for the quarter ended March 31, 2021 (the "Form 10-Q") in a timely fashion. The Notice advised the Company that it was not in compliance with Nasdaq’s continued listing requirements under the timely filing criteria established in Nasdaq Listing Rule 5250(c)(1). Under Nasdaq rules, the Company has 60 calendar days from receipt of the Notice (May 28, 2021), or until July 27, 2021, to submit a plan to regain compliance with the Rule. If Nasdaq accepts the Company's plan, then Nasdaq may grant an exception of up to 180 calendar days from the due date of the Form 10-Q (May 24, 2021), or until November 22, 2021, to regain compliance. However, there can be no assurance that Nasdaq will accept the Company's plan to regain compliance or that the Company will be able to regain compliance within any extension period granted by Nasdaq. If Nasdaq does not accept the Company’s plan, then the Company will have the opportunity to appeal that decision to a Nasdaq hearings panel. As noted above, the Company is working diligently to complete its Form 10-Q. The Company intends to file the Form 10-Q as soon as practicable to regain compliance with the Nasdaq Listing Rules. No assurance can be given that the Company will be able to regain compliance with the aforementioned listing requirement or maintain compliance with the other continued listing requirements set forth in the Nasdaq Listing Rules.공시 • May 18Epiphany Technology Acquisition Corp. announced delayed 10-Q filingOn 05/17/2021, Epiphany Technology Acquisition Corp. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.지급의 안정성과 성장배당 데이터 가져오는 중안정적인 배당: 과거에 EPHY 의 주당 배당금이 안정적이었는지 판단하기에는 데이터가 부족합니다.배당금 증가: EPHY 의 배당금 지급이 증가했는지 판단하기에는 데이터가 부족합니다.배당 수익률 vs 시장Epiphany Technology Acquisition 배당 수익률 vs 시장EPHY의 배당 수익률은 시장과 어떻게 비교되나요?구분배당 수익률회사 (EPHY)n/a시장 하위 25% (US)1.4%시장 상위 25% (US)4.2%업계 평균 (Capital Markets)2.1%분석가 예측 (EPHY) (최대 3년)n/a주목할만한 배당금: 회사가 최근 지급을 보고하지 않았기 때문에 하위 25%의 배당금 지급자에 대해 EPHY 의 배당 수익률을 평가할 수 없습니다.고배당: 회사가 최근 지급을 보고하지 않았기 때문에 배당금 지급자의 상위 25%에 대해 EPHY 의 배당 수익률을 평가할 수 없습니다.주주 대상 이익 배당수익 보장: 배당금 지급이 수익으로 충당되는지 확인하기 위해 EPHY 의 지급 비율을 계산하기에는 데이터가 부족합니다.주주 현금 배당현금 흐름 범위: EPHY 에서 지급을 보고하지 않았기 때문에 배당 지속 가능성을 계산할 수 없습니다.높은 배당을 제공하는 우량 기업 찾기7D1Y7D1Y7D1YUS 시장에서 배당이 강한 기업.View Management기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2023/01/15 20:58종가2023/01/12 00:00수익2022/09/30연간 수익2021/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Epiphany Technology Acquisition Corp.는 0명의 분석가가 다루고 있습니다. 이 중 명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
공시 • Jan 14Epiphany Technology Acquisition Corp.(NasdaqCM:EPHY) dropped from NASDAQ Composite IndexEpiphany Technology Acquisition Corp. has been dropped from NASDAQ Composite Index .
Board Change • Dec 31High number of new and inexperienced directorsThere are 10 new directors who have joined the board in the last 3 years. The company's board is composed of: 10 new directors. 2 experienced directors. No highly experienced directors. Co-CEO, CFO & Director Peter Bell is the most experienced director on the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.
공시 • Sep 24Epiphany Technology Acquisition Corp. Appoints Board of DirectorsEffective September 16, 2022, the board of directors of Epiphany Technology Acquisition Corp. approved an increase in the size of the Board from seven (7) directors to eleven (11) directors and elected Ross Haghighat, Stephen Sherwin, Louis Lange and Ronald Eastman as members of the Board to fill the vacancies created by the increase. The Board determined that each Messrs. Stephen Sherwin, Louis Lange and Ronald Eastman is an “independent director” as defined in the Nasdaq listing standards and applicable rules of the Securities and Exchange Commission. Ross Haghighat has served as Chief Executive Officer, Chief Financial Officer and a Director of BioPlus Acquisition Corp. since December 2021. Mr. Haghighat is the founding partner at Jasper Capital Partners and Chairman of Triton Systems Inc. Mr. Haghighat has been a founder, co-founder, and board member of more than a dozen private and public technology companies in the US, Europe, China and Australia. During Mr. Haghighat’s expansive career as an operator, he generated billions in shareholder value through his roles transforming companies from early-stage technology firms to successful corporations, as well as integrated divisions of Fortune 500 companies. From 1994 to 2001, Mr. Haghighat co-founded and led CoreTek Inc. Mr. Haghighat currently serves on the Board of Directors at Chinook Therapeutics Inc., where Mr. Haghighat is Chairman of the Transaction Committee; CITIC Capital Acquisition Corp., where Mr. Haghighat also serves as Chair of the Audit Committee of Fluence Corporation Ltd., where Mr. Haghighat serves as Vice Chairman; Angel Medical Systems Inc., where Mr. Haghighat serves as Lead Director and FRX Polymers Inc., where Mr. Haghighat serves as Chairman. Mr. Haghighat received a Bachelor of Science in Advanced Materials Engineering from Rutgers University and Master of Science in Organometalic Chemistry from Rutgers University, as well as an MBA from Boston College — Wallace E Carroll School of Management. Mr. Haghighat is well qualified to serve on the Board due to his extensive operating, investing and board experience in the biotechnology industry. Ronald Eastman Since December 2021, Ronald Eastman has served as Vice Chairman of BioPlus Acquisition Corp. Mr. Eastman has over 40 years of experience in building and leading both publicly-traded and private healthcare businesses. Mr. Eastman is currently a Senior Advisor of EW Healthcare Partners (EW), where he previously served for 15 years as Managing Director of multiple funds before transitioning to Senior Advisor in 2021. Mr. Eastman led and served on the Board of Directors of EW’s investments in ProteinSimple Inc. (acquired by Bio-Techne Corporation), Corium Inc. (acquired by Gurnet Point Capital), and Open Monoclonal Technology Inc. (acquired by Ligand Pharmaceuticals Inc.). He also currently serves on the Board of Directors of EW portfolio company Suneva Medical Inc. Mr. Eastman began his career at American Cyanamid Company, which was acquired by American Home Products (now Pfizer Inc.), where Mr. Eastman spent 15 years managing various pharmaceutical products, divisions, and subsidiaries in the U.S. and overseas. Later as CEO of Geron Corporation, Mr. Eastman led the company’s growth from a venture-backed start-up to a publicly traded pioneer in the fields of regenerative medicine and cancer. As CEO of Rinat Neuroscience Corporation with the support of EW in late 2001, Mr. Eastman led the effort to build the first company dedicated to discovering and developing large molecule drugs for treating nervous system disorders. Rinat Neuroscience was acquired by Pfizer Inc. in 2006. Mr. Eastman has also previously served as a board member of Revance Therapeutics Inc., the Biotechnology Innovation Organization, and as a Trustee of the Buck Institute for Research on Aging. Mr. Eastman has a Bachelor of Arts degree from Williams College and a Master of Business Administration degree from Columbia University. Mr. Eastman is well qualified to serve on the Board due to his extensive operating, investing and board experience in the biotechnology industry.
공시 • Sep 23Epiphany Technology Acquisition Corp. Appoints Ross Haghighat as Co-Chief Executive OfficerThe board appointed Mr. Ross Haghighat as Co-Chief Executive Officer of Epiphany Technology Acquisition Corp., effective September 16, 2022. Ross Haghighat has served as Chief Executive Officer, Chief Financial Officer and a Director of BioPlus Acquisition Corp. since December 2021. Mr. Haghighat is the founding partner at Jasper Capital Partners and Chairman of Triton Systems Inc. Mr. Haghighat has been a founder, co-founder, and board member of more than a dozen private and public technology companies in the US, Europe, China and Australia. During Mr. Haghighat’s expansive career as an operator, he generated billions in shareholder value through his roles transforming companies from early-stage technology firms to successful corporations, as well as integrated divisions of Fortune 500 companies. From 1994 to 2001, Mr. Haghighat co-founded and led CoreTek Inc. Mr. Haghighat currently serves on the Board of Directors at Chinook Therapeutics Inc., where Mr. Haghighat is Chairman of the Transaction Committee; CITIC Capital Acquisition Corp., where Mr. Haghighat also serves as Chair of the Audit Committee of Fluence Corporation Ltd., where Mr. Haghighat serves as Vice Chairman; Angel Medical Systems Inc., where Mr. Haghighat serves as Lead Director and FRX Polymers Inc., where Mr. Haghighat serves as Chairman. Mr. Haghighat received a Bachelor of Science in Advanced Materials Engineering from Rutgers University and Master of Science in Organometalic Chemistry from Rutgers University, as well as an MBA from Boston College — Wallace E Carroll School of Management. Mr. Haghighat is well qualified to serve on the Board due to his extensive operating, investing and board experience in the biotechnology industry.
공시 • Jun 05Epiphany Technology Acquisition Announces Receipt of Notice from Nasdaq Regarding Late Filing of Quarterly Report on Form 10-QEpiphany Technology Acquisition Corp. announced that it has received a notice (“Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market (“Nasdaq”) as a result of its failure to file its Quarterly Report on Form 10-Q for the quarter ended March 31, 2021 (the "Form 10-Q") in a timely fashion. The Notice advised the Company that it was not in compliance with Nasdaq’s continued listing requirements under the timely filing criteria established in Nasdaq Listing Rule 5250(c)(1). Under Nasdaq rules, the Company has 60 calendar days from receipt of the Notice (May 28, 2021), or until July 27, 2021, to submit a plan to regain compliance with the Rule. If Nasdaq accepts the Company's plan, then Nasdaq may grant an exception of up to 180 calendar days from the due date of the Form 10-Q (May 24, 2021), or until November 22, 2021, to regain compliance. However, there can be no assurance that Nasdaq will accept the Company's plan to regain compliance or that the Company will be able to regain compliance within any extension period granted by Nasdaq. If Nasdaq does not accept the Company’s plan, then the Company will have the opportunity to appeal that decision to a Nasdaq hearings panel. As noted above, the Company is working diligently to complete its Form 10-Q. The Company intends to file the Form 10-Q as soon as practicable to regain compliance with the Nasdaq Listing Rules. No assurance can be given that the Company will be able to regain compliance with the aforementioned listing requirement or maintain compliance with the other continued listing requirements set forth in the Nasdaq Listing Rules.
공시 • May 18Epiphany Technology Acquisition Corp. announced delayed 10-Q filingOn 05/17/2021, Epiphany Technology Acquisition Corp. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.